文献速递泌尿生殖MRUS

自动化混合多维MRI工具用于前列腺癌检测的前瞻性验证:与基于PI-RADS评估的靶向活检比较

Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.
PubMed 文献 · Radiol Imaging Cancer · 2025-01-01

这项前瞻性临床试验纳入91例已知或疑似前列腺癌的男性参与者,在MRI/US融合活检前比较自动化HM-MRI工具与专家放射科医师基于PI-RADS的mpMRI评估。HM-MRI在参与者层面准确度55% vs 44%(P=0.02)、特异度36% vs 14%(P=0.002),在病灶层面准确度58% vs 39%(P<0.001)、阳性预测值31% vs 22%(P=0.004),在六分区层面AUC 0.76 vs 0.65(P<0.001)、准确度83.9% vs 79.0%(P=0.006)。结论认为HM-MRI有潜力通过为PI-RADS评估提供补充信息来改善MRI/US融合活检结果。

要点

  • HM-MRI工具自动识别上皮>40%且管腔<20%、最小面积25 mm²的可疑前列腺癌区域。
  • 参与者层面HM-MRI准确度55% vs mpMRI 44%,特异度36% vs 14%。
  • 病灶层面HM-MRI准确度58% vs mpMRI 39%,阳性预测值31% vs 22%。

核心结论

  • 本研究表明HM-MRI有潜力通过为专家放射科医师基于PI-RADS的评估提供补充信息来改善MRI/US融合活检的前列腺癌检测结果。

研究设计与样本

  • 前瞻性临床试验(ClinicalTrials.gov注册号NCT03585660),纳入91例已知或疑似前列腺癌的男性参与者(平均年龄65岁±8[SD]),2018年8月至2023年3月期间接受3-T MRI常规mpMRI方案和HM-MRI检查后行活检。

诊断标准与关键数值

  • HM-MRI工具采用三室模型计算组织成分,识别上皮>40%且管腔<20%、满足最小尺寸25 mm²的可疑前列腺癌区域。

临床应用与阅片要点

  • HM-MRI工具在专家放射科医师mpMRI判读(≥PI-RADS 3)所选活检靶点之外,每例参与者最多自动追加两个活检靶点;同时获取12针经直肠超声引导六分区随机活检芯。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the use of an automated hybrid multidimensional MRI (HM-MRI)-based tool to prospectively identify prostate cancer targets before MRI/US fusion biopsy in comparison with Prostate Imaging and Reporting Data System (PI-RADS)-based multiparametric MRI (mpMRI) evaluation by expert radiologists. Materials and Methods In this prospective clinical trial (ClinicalTrials.gov registration no. NCT03585660), 91 male participants (mean age, 65 years ± 8 [SD]) with known or suspected prostate cancer underwent 3-T MRI with a conventional mpMRI protocol and HM-MRI followed by subsequent biopsy between August 2018 and March 2023. Using the HM-MRI tool, tissue composition was calculated using a three-compartment model, and suspected prostate cancer regions with elevated epithelium (>40%) and reduced lumen (<20%) meeting the minimum size requirement of 25 mm2 were identified. Up to two additional biopsy targets per participant were automatically selected with the HM-MRI tool in addition to the biopsy targets selected based on an expert radiologist's mpMRI interpretation (≥PI-RADS 3) using an MRI/US fusion biopsy device. Additional 12-core transrectal US-guided sextant random biopsy cores were also obtained. Detection of clinically significant prostate cancer (≥Gleason 3+4) was compared between HM-MRI and mpMRI by calculating area under the receiver operating characteristic curve and diagnostic accuracy metrics. Results The diagnostic performance of HM-MRI was either higher than mpMRI or showed no evidence of a difference when compared with mpMRI. On a per-participant basis, HM-MRI had significantly higher accuracy (55% vs 44%; P = .02) and specificity (36% vs 14%: P = .002) than mpMRI. On a per-lesion basis, HM-MRI had significantly higher accuracy (58% vs 39%; P < .001) and positive predictive value (31% vs 22%; P = .004) compared with mpMRI. Only one lesion was missed when using the combination of mpMRI and HM-MRI. On a per-sextant basis, HM-MRI showed significantly better performance than mpMRI for all metrics, including primary end points of the area under the receiver operating characteristic curve (0.76 vs 0.65; P < .001) and accuracy (83.9% vs 79.0%; P = .006). Conclusion This study demonstrates that HM-MRI has the potential to improve MRI/US fusion biopsy results for prostate cancer detection by providing complementary information to PI-RADS-based evaluation by expert radiologists. Keywords: Prostate Cancer, Hybrid Multidimensional MRI, Multiparametric MRI, PI-RADS Clinical trial registration no. NCT03585660 ©RSNA, 2025.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Chatterjee A, Yousuf AN, Engelmann R, et al. Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment. Radiol Imaging Cancer. 2025. PMID: 39836080. doi:10.1148/rycan.240156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。